-
Mashup Score: 2Illumina and Pillar Biosciences partner to improve access to personalized cancer treatment options - 9 month(s) ago
Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, and Pillar Biosciences Inc., the pioneers of Decision Medicine™, today announced a strategic partnership to make Pillar’s suite of oncology assays commercially available globally as part of the Illumina portfolio of oncology products. The agreement will result in an unprecedented offering of complementary next-generation sequencing solutions that will enhance the efficiency, accuracy, and cost-effectiveness of oncology testing through advanced sequencing techniques, improving patient access to personalized cancer treatment options. “We are proud to partner with Pillar to provide products that will improve care for patients with advanced and high-risk cancer,” said Phil Febbo, chief medical officer of Illumina. “By leveraging Pillar’s targeted sequencing technology alongside Illumina’s state-of-the-art sequencing and bioinformatics solutions, we will enable rapid and focused genomic profiling
Source: investor.illumina.comCategories: Latest Headlines, Oncologists1Tweet
-
Mashup Score: 3Press Release - 10 month(s) ago
Alliance aims to accelerate therapeutic development and expand the diversity of genomic data through inclusion of more samples from currently underrepresented ancestries , /PRNewswire/ — Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, in collaboration with Nashville Biosciences, LLC, a leading clinical and genomic data company…
Source: www.illumina.comCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0Addressing the genomics education gap - 11 month(s) ago
With limited space in the curricula for genomics, residents and physicians are turning to other sources for training
Source: www.illumina.comCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0
Clopidogrel is less effective at preventing subsequent strokes in patients with certain variations in the CYP2C19 gene and testing could aid treatment selection.
Source: GenomeWebCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 2Biden nominates Monica Bertagnolli to lead National Institutes of Health - 12 month(s) ago
Surgical oncologist would be the agency’s 17th director if confirmed by Senate
Source: www.science.orgCategories: Latest Headlines, Oncologists1Tweet
-
Mashup Score: 4Press Release - 12 month(s) ago
, /PRNewswire/ — Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today recognized the progress and impact of genomic technologies on pathogen preparedness and response. Following the boost in sequencing infrastructure and capabilities driven by the COVID-19 pandemic, today genomic technologies are enabling public health agencies and health care…
Source: www.illumina.comCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 1A Step-Change in Whole Genome Sequencing Coverage | LinkedIn - 1 year(s) ago
United Healthcare (UHC) and Cigna recently changed their coverage policies to include whole genome sequencing (WGS) to diagnose genetic diseases in patients who meet eligibility criteria based on their clinical presentations: multiple congenital anomalies, intellectual disability, global developmental delay and others. UHC and Cigna are the largest and fourth largest commercial health insurance…
Source: www.linkedin.comCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0Illumina's revolutionary NovaSeq X exceeds 200th order milestone in first quarter 2023 - 1 year(s) ago
/PRNewswire/ — Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced it has already exceeded more than…
Source: www.prnewswire.comCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 2
For our anniversary, we’re counting the ways our technology has changed health care and the environment
Source: www.illumina.comCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 1As Use of Large Cancer Panels and Whole-Genome Sequencing Expands, Illumina Plans to Future-Proof NGS Interpretation and Reporting - 1 year(s) ago
Illumina’s new software platform, designed to reduce tertiary analysis time and ease reporting, launches in multiple global markets as experts say the volume of clinical NGS data is ballooning.
Source: GenomeWebCategories: Hem/Oncs, Latest HeadlinesTweet
Our partnership with @Pillar_Bio will combine their targeted panels with @illumina 's NGS and bioinformatics for rapid #genomic profiling of tumors when focused testing is needed. Improving care for patients with advanced and high-risk cancer, together. https://t.co/oR31IAvH3l